Lialda (Mesalazine): Main Uses and Benefits

Lialda, a delayed-release tablet formulation of mesalamine (5-aminosalicylic acid or 5-ASA), is considered relevant for use in conditions characterized by periods of heightened symptoms within the gastrointestinal tract. Specifically, Lialda is an anti-inflammatory medication that plays a role in managing active, mild to moderate ulcerative colitis.

The medication is applied in addressing the active phase and may be part of symptomatic management during periods of remission. The drug is commonly used across conditions presenting with acute episodes to support the patient during difficult episodes by easing distress. It is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant when supportive symptom management is appropriate. The core indications are managing the active condition and supportive care in ulcerative colitis.

The drug is relevant for easing discomfort and contributes to improved comfort during periods of heightened symptoms. The medication may assist with easing common symptoms that interfere with daily functioning, such as diarrhea, rectal bleeding, and abdominal discomfort associated with the condition.

“The drug contributes to support general well-being during symptomatic phases and helps ease the overall symptom burden.”

Quick Fact: May assist with Symptoms related to physical discomfort

Regulatory References

1. NIH MedlinePlus overview of mesalamine

Who Can and Cannot Use Lialda (Mesalazine)?

Lialda eligibility is strictly defined by government regulatory agencies based on hypersensitivity, age, and pre-existing medical conditions.

---

Contraindicated Populations

Lialda is contraindicated and must not be used in individuals with known or suspected hypersensitivity to salicylates (including mesalamine) or aminosalicylates, or to any of the product's inactive ingredients. Furthermore, official regulatory documents state the drug is not recommended or contraindicated in patients with severe renal impairment or severe hepatic impairment.

---

Eligibility and Restricted Use

Population/Condition	Regulatory Status
Adults	Approved for use in ulcerative colitis.
Pediatrics	Use not established in children under five years of age or weighing less than 24 kg.
Renal/Hepatic Impairment	Use with caution; monitoring of organ function is required.
Pregnancy/Lactation	Use caution; benefit must outweigh the risk as determined by a healthcare provider.
GI Obstruction	Avoid in patients at risk of Upper GI Tract Obstruction (e.g., pyloric stenosis).

Use requires caution in geriatric patients, those with a history of sulfasalazine hypersensitivity, or conditions predisposing to myocarditis.

Interactions with other medicines and products

Official regulatory documents indicate that Lialda (Mesalazine) has documented interactions with specific classes of medicinal products, requiring close monitoring and management.

Documented Interaction Categories

The following products and categories are noted in official labeling for their interaction potential:

Interacting Product Category	Interacting Medicines (Explicitly Listed)	Interaction Outcome/Requirement
Purine Antimetabolites	Azathioprine, 6-Mercaptopurine	Increased risk of blood disorders (myelotoxicity). Monitoring is required of complete blood cell counts and platelet counts.
Nephrotoxic Agents	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Increased risk of kidney toxicity (nephrotoxicity). Monitoring is required for changes in renal function.
Anticoagulants	Warfarin	Potential for altered effects of the anticoagulant. Monitoring is required of Prothrombin Time and International Normalized Ratio (INR).

Procedural Constraints

The use of mesalamine may interfere with certain laboratory tests, leading to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. An alternative, selective assay should be considered when this specific test is required. The overall regulatory profile defines specific, clinically significant management requirements for co-administration rather than imposing absolute restrictions.

The mechanism of mesalazine (5-aminosalicylic acid, 5-ASA) is primarily topical, relying on its local delivery to the colonic mucosa to execute an action influencing multiple anti-inflammatory pathways at the molecular level.

Inhibition of Pro-inflammatory Mediators

Mesalazine acts as an inhibitor of key enzymes in the arachidonic acid pathway, notably Cyclooxygenase (COX) and Lipoxygenase (LOX). By blocking these targets, the compound reduces the local synthesis of pro-inflammatory signaling molecules like prostaglandins and leukotrienes. This mechanistic domain contributes to a lower concentration of pro-inflammatory mediators and decreased migration of inflammatory cells into the colonic lining.

Modulation of Genetic Signaling Pathways

A crucial part of the mechanism is the modulation of transcription factors that control inflammatory gene expression. Mesalazine inhibits the activation of Nuclear factor-kappa B (NF-κB), thereby suppressing the production of pro-inflammatory cytokines (e.g., TNF-α). Concurrently, it acts as an agonist of the nuclear receptor Peroxisome proliferator-activated receptor gamma (PPAR-γ), which promotes the expression of anti-inflammatory genes. This dual genetic action modulates the local immune cell activity toward a less reactive state.

Reduction of Oxidative Stress

Mesalazine also possesses significant antioxidant properties. It acts as a scavenger of Reactive Oxygen Species (ROS) and free radicals, which are produced in large quantities by activated immune cells and contribute to cellular stress. By neutralizing these compounds at the tissue level, this action reduces the localized oxidative load on colonic epithelial cells and contributes to maintaining structural function.

How to Use Lialda (Mesalazine): Official Administration Guidelines

Lialda is an oral, delayed-release tablet intended for the treatment of ulcerative colitis. Adherence to the official administration rules is critical for ensuring proper drug delivery.

---

Administration Rules

• Route: Oral (swallowed by mouth).
• Frequency: Doses must be taken once daily.
• Food Requirement: Lialda tablets must be taken with food (with a meal) to optimize the drug's release characteristics.
• Procedural Constraint: The tablets are delayed-release and must be swallowed whole. They must not be split, crushed, or chewed as this will compromise the coating designed to deliver the medicine to the colon.

Dosing and Schedule

Patient Group	Treatment Phase	Standard Dose (Once Daily)	Strength
Adults	Induction of Remission	2.4 g to 4.8 g	1.2 g tablets (2 to 4)
Adults	Maintenance of Remission	2.4 g	1.2 g tablets (2)
Pediatric (≥ 24 kg)	Induction / Maintenance	Weight-based regimen	1.2 g tablets

---

Special Instructions

• Missed Dose: If a dose is missed, take the next dose at the regular scheduled time. Do not take two doses at the same time to compensate for a missed dose.
• Pediatrics: Approved for pediatric patients who weigh at least 24 kg and are able to swallow tablets whole. Dosing is strictly weight-based.
• Fluid Intake: Adequate fluid intake is recommended during treatment.

Evidence Overview for Lialda (Mesalazine)

This summary describes the evidence that has been reported in clinical trials and is not a substitute for clinical advice.

---

Evidence for Inducing Remission in Active Ulcerative Colitis

Research for this indication was studied for its use primarily through short-term, randomized, placebo-controlled clinical trials in adults with active, mild-to-moderate ulcerative colitis. These studies were applied in research contexts to observe how symptoms evolved over defined time intervals, typically around eight weeks. The studies examined the proportion of patients whose condition achieved an observed state of remission, alongside measuring patient-reported outcomes describing discomfort, such as the frequency of stools and rectal bleeding.

The studies reported measured differences in observed remission rates between the study drug groups and the placebo group. The data show patterns related to symptom patterns over the short duration of the active disease phase. However, follow-up durations were limited to these short intervals, and therefore long-term effects are not fully established based on this initial evidence.

---

Evidence for Maintaining Remission and Research Limitations

For the maintenance of condition stability, the research base includes longer-term randomized trials and observational studies. These efforts have been used to examine the maintenance of condition stability and the reduction in the rate of disease relapse in patients whose condition was already stable. The data show patterns related to how long stability was observed over extended time intervals.

Evidence was evaluated in various populations, but data for certain groups remain insufficient. For instance, the medicine was observed in pediatric populations (children ages 5 to 17), but evidence for this group is still emerging, which means that certainty remains low regarding the full characteristics of use in children.

Comparative evidence is lacking for direct comparisons between this specific formulation and all other mesalamine products. Furthermore, large research reports highlight how patient adherence (the consistency of taking the medicine as prescribed) may influence long-term outcomes, introducing a recognized research limitation frame in real-world settings.

Common questions about Lialda (Mesalazine) (FAQ)

---

Q: What should I do if I accidentally forget to take my Lialda dose?

According to the official product information, if a dose is missed, official guidance indicates that the next scheduled dose should be taken at the regular time. Official instructions caution against taking two doses at the same time to make up for the missed one.

---

Q: What is the usual dose of Lialda for an adult to maintain remission of ulcerative colitis?

For adults maintaining remission of ulcerative colitis, the official recommended dosage is 2.4 g daily. This dosage is administered once daily with a meal, consistent with regulatory guidelines.

---

Q: How does Lialda work to reduce inflammation in the colon?

Lialda's active ingredient, mesalazine, is an aminosalicylate. Official information indicates the drug's mechanism is based on its local anti-inflammatory action on the colon lining, characteristic of its pharmacological class.

---

Q: What is the risk of taking Lialda while also taking Azathioprine or Warfarin?

Regulatory documents indicate that taking Lialda with medicines like azathioprine or 6-mercaptopurine increases the risk of blood disorders; management of this interaction often involves monitoring of blood counts. Concomitant use with warfarin may alter its effects, and management of this interaction involves monitoring of Prothrombin Time and INR.

---

Q: Are there any dietary restrictions I need to follow while I am on Lialda?

Lialda tablets are required to be taken with food, as this administration condition helps to optimize the drug's release characteristics. Beyond this requirement to take it with a meal, no specific food or beverage restrictions are typically listed in the official product labeling.

---

Q: How long does it typically take for Lialda to start working for ulcerative colitis symptoms?

Clinical studies used to evaluate Lialda's effectiveness for active ulcerative colitis were typically conducted over an 8-week period. This time frame reflects the duration used in clinical trials to assess the drug's effectiveness for inducing remission.

---

Q: Is it safe for a pregnant or breastfeeding woman to take Lialda?

Official information indicates that mesalazine, the active ingredient, can pass into the placenta and breast milk at low levels. Use during pregnancy or lactation requires caution, and the benefit must be weighed against potential hazards. If diarrhea occurs in a breastfed infant, regulatory guidance suggests that breastfeeding should be discontinued.

How to Store and Dispose of Lialda (Mesalazine)?

The official guidelines for Lialda storage and disposal are based on preserving the medication's stability and ensuring safety. The tablets must be stored at Controlled Room Temperature, specifically between 15 C and 25 C (59 F and 77 F), away from excess heat.

Storage and Handling

To protect the formulation, the medication must be shielded from light and excess moisture, requiring storage in the original container, which should be kept tightly closed. The delayed-release tablets must not be split, crushed, or chewed. All medication must be stored securely, out of the reach and sight of children.

Disposal

Official disposal rules state that Lialda must not be flushed down the toilet or poured into a drain. The recommended disposal method is to use a community drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and disposed of in the household trash.